| # | Title | Journal | Year | Citations |
|---|
| 1 | Measuring Adherence to Antiretroviral Therapy in a Diverse Population Using a Visual Analogue Scale | HIV Clinical Trials | 2004 | 320 |
| 2 | Self-Reported Symptoms After Initiation of a Protease Inhibitor in HIV-Infected Patients and Their Impact on Adherence to HAART | HIV Clinical Trials | 2001 | 214 |
| 3 | The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients | HIV Clinical Trials | 2007 | 160 |
| 4 | Aging and HIV Infection: A Comparison Between Older HIV-Infected Persons and the General Population | HIV Clinical Trials | 2010 | 153 |
| 5 | Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients | HIV Clinical Trials | 2007 | 132 |
| 6 | “White Coat Compliance” Limits the Reliability of Therapeutic Drug Monitoring in HIV-1—Infected Patients | HIV Clinical Trials | 2008 | 111 |
| 7 | Predictors of Retention in HIV Care Among a National Cohort of US Veterans | HIV Clinical Trials | 2009 | 111 |
| 8 | Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United StatesRevised November 3, 2000 | HIV Clinical Trials | 2001 | 109 |
| 9 | Efficacy of an Educational and Counseling Intervention on Adherence to Highly Active Antiretroviral Therapy: French Prospective Controlled Study | HIV Clinical Trials | 2003 | 109 |
| 10 | Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine | HIV Clinical Trials | 2003 | 106 |
| 11 | Guidelines for the use of antiretroviral agents in pediatric HIV infection, January 7, 2000 | HIV Clinical Trials | 2000 | 103 |
| 12 | The Efficacy and Safety of ProbioticLactobacillus rhamnosusGG on Prolonged, Noninfectious Diarrhea in HIV Patients on Antiretroviral Therapy: A Randomized, Placebo-Controlled, Crossover Study | HIV Clinical Trials | 2004 | 102 |
| 13 | Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s) | HIV Clinical Trials | 2009 | 100 |
| 14 | Safety and Tolerance of Efavirenz in Different Antiretroviral Regimens: Results from a National Multicenter Prospective Study in 1,033 HIV-Infected Patients | HIV Clinical Trials | 2002 | 99 |
| 15 | Monitoring Medication Adherence by Unannounced Pill Counts Conducted by Telephone: Reliability and Criterion-Related Validity | HIV Clinical Trials | 2008 | 99 |
| 16 | Impact of a Selenium Chemoprevention Clinical Trial on Hospital Admissions of HIV-Infected Participants | HIV Clinical Trials | 2002 | 98 |
| 17 | Measuring Adherence to Antiretroviral Medications in Clinical Trials | HIV Clinical Trials | 2000 | 96 |
| 18 | Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor | HIV Clinical Trials | 2013 | 95 |
| 19 | Clinical Utility of Monitoring Serum Cryptococcal Antigen (sCRAG) Titers in Patients with AIDS-Related Cryptococcal Disease | HIV Clinical Trials | 2000 | 94 |
| 20 | Comparison of Functional Status Instruments in HIV-Infected Adults on Effective Antiretroviral Therapy | HIV Clinical Trials | 2012 | 93 |
| 21 | Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV-Infected Individuals from 40 United States Cities | HIV Clinical Trials | 2007 | 90 |
| 22 | Evaluation of the Patient Medication Adherence Questionnaire As a Tool for Self-Reported Adherence Assessment in HIV-Infected Patients on Antiretroviral Regimens | HIV Clinical Trials | 2001 | 86 |
| 23 | Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlations | HIV Clinical Trials | 2002 | 86 |
| 24 | Elevated Blood Pressure in HIV-Infected Individuals Receiving Highly Active Antiretroviral Therapy | HIV Clinical Trials | 2003 | 86 |
| 25 | World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects Revised October 7, 2000 | HIV Clinical Trials | 2001 | 85 |
| 26 | A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results | HIV Clinical Trials | 2012 | 85 |
| 27 | Simpler Regimens May Enhance Adherence to Antiretrovirals in HIV-Infected Patients | HIV Clinical Trials | 2002 | 81 |
| 28 | Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients | HIV Clinical Trials | 2008 | 80 |
| 29 | Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection | HIV Clinical Trials | 2000 | 80 |
| 30 | Pilot Study of a Novel Short-Cycle Antiretroviral Treatment Interruption Strategy: 48-Week Results of the Five-Days-On, Two-Days-Off (FOTO) Study | HIV Clinical Trials | 2007 | 76 |
| 31 | Low-Level Viremia in HIV-1 Infection: Consequences and Implications for Switching to a New Regimen | HIV Clinical Trials | 2009 | 76 |
| 32 | Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results | HIV Clinical Trials | 2011 | 76 |
| 33 | Alendronate Reduces Bone Resorption in HIV-Associated Osteopenia/Osteoporosis | HIV Clinical Trials | 2004 | 74 |
| 34 | Comparison of Neuropsychiatric Side Effects in an Observational Cohort of Efavirenz- and Protease Inhibitor-Treated Patients | HIV Clinical Trials | 2005 | 73 |
| 35 | Relationship Between Low Bone Mineral Density and Highly Active Antiretroviral Therapy Including Protease Inhibitors in HIV-Infected Patients | HIV Clinical Trials | 2003 | 72 |
| 36 | AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT): Rationale, Design, and Baseline Characteristics | HIV Clinical Trials | 2008 | 72 |
| 37 | Electronic monitoring: Adherence assessment or intervention? | HIV Clinical Trials | 2002 | 70 |
| 38 | Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers | HIV Clinical Trials | 2004 | 69 |
| 39 | Self-Reported Fatigue and Depressive Symptoms as Main Indicators of the Quality of Life (QOL) of Patients Living with HIV and Hepatitis C: Implications for Clinical Management and Future Research | HIV Clinical Trials | 2007 | 68 |
| 40 | Low Rates of Neurocognitive Impairment Are Observed in Neuro-Asymptomatic HIV-Infected Subjects on Effective Antiretroviral Therapy | HIV Clinical Trials | 2011 | 67 |
| 41 | Health-Related Quality of Life in Individuals Infected with HIV in the Era of HAART | HIV Clinical Trials | 2001 | 66 |
| 42 | Factors associated with the failure of HIV-positive persons to return for scheduled medical visits | HIV Clinical Trials | 2002 | 66 |
| 43 | A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128 | HIV Clinical Trials | 2003 | 66 |
| 44 | Reservoirs, Sanctuaries, and Residual Disease: The Hiding Spots of HIV-1 | HIV Clinical Trials | 2003 | 66 |
| 45 | Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients | HIV Clinical Trials | 2004 | 66 |
| 46 | Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial | HIV Clinical Trials | 2012 | 66 |
| 47 | Comparison of Nevirapine- and Efavirenz-Containing Antiretroviral Regimens in Antiretroviral-Naïve Patients: A Cohort Study | HIV Clinical Trials | 2002 | 64 |
| 48 | Therapeutic Options for the Management of Oropharyngeal and Esophageal Candidiasis in HIV/AIDS Patients | HIV Clinical Trials | 2000 | 63 |
| 49 | Cost-Effectiveness of Lopinavir/Ritonavir Versus Nelfinavir As the First-Line Highly Active Antiretroviral Therapy Regimen for HIV Infection | HIV Clinical Trials | 2004 | 62 |
| 50 | The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching Therapy | HIV Clinical Trials | 2007 | 62 |
